Abstract
Twenty-eight patients with progressive symptomatic bone metastases from breast cancer received (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) 30 mg in 500 ml of 0.9% saline infused over 2 h every 14 days. No other systemic therapy for breast cancer was prescribed. All patients had progressed on at least one previous systemic treatment. APD was continued until the disease progressed. Patients were assessed for objective response by the UICC criteria. In addition, subjective response was determined by a pain questionnaire. Radiological evidence of bone healing with sclerosis of lytic disease (UICC partial response) was seen in 4 patients. The median duration of response was 10 months. Eleven patients had stable disease for at least 3 months (median 5 months) and 9 progressed. Symptomatic response occurred in 9 patients and 12 reported an improvement in quality of life. Treatment was tolerated well with no significant toxicity. In conclusion, long-term inhibition of bone destruction is possible with APD therapy alone and both subjective and objective responses are seen.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Coleman, R., Woll, P., Miles, M. et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Br J Cancer 58, 621–625 (1988). https://doi.org/10.1038/bjc.1988.272
Issue Date:
DOI: https://doi.org/10.1038/bjc.1988.272
This article is cited by
-
Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases
Supportive Care in Cancer (2012)
-
Imaging response to systemic therapy for bone metastases
European Radiology (2009)
-
The farnesyl transferase inhibitor R115777 (Zarnestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa®) and Pamidronate
Oncogene (2004)
-
Clinical efficacy of bisphosphonate therapy for bone metastasis from breast cancer
Breast Cancer (2003)
-
Bisphosphonate therapy for bone metastases from Breast Cancer: Clinical results and a new therapeutic approach
Breast Cancer (2000)